Cargando…

Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently

Activation of receptor tyrosine kinases needs tight control by tyrosine phosphatases to keep their normal function. In this study, we investigated the regulation of activation of the type III receptor tyrosine kinase KIT by protein tyrosine phosphatase receptor type E (PTPRE). We found that PTPRE ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shaoting, Zhang, Liangying, Jiang, Zongying, Guo, Yue, Zhao, Hui, Sun, Jianmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937656/ https://www.ncbi.nlm.nih.gov/pubmed/33732906 http://dx.doi.org/10.1016/j.bbrep.2021.100974

Ejemplares similares

Tuning the Protein Phosphorylation by Receptor Type Protein Tyrosine Phosphatase Epsilon (PTPRE) in Normal and Cancer Cells
por: Liang, Jinping, et al.
Publicado: (2019)

Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1
Publicado: (1996)

LncRNA PTPRE-AS1 modulates M2 macrophage activation and inflammatory diseases by epigenetic promotion of PTPRE
por: Han, Xiao, et al.
Publicado: (2019)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

A novel anti‐c‐Kit antibody–drug conjugate to treat wild‐type and activating‐mutant c‐Kit‐positive tumors
por: Kim, Jin‐Ock, et al.
Publicado: (2021)

Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
por: Zhu, Guangrong, et al.
Publicado: (2020)

Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST
por: Astolfi, Annalisa, et al.
Publicado: (2020)

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma
por: Klug, Lillian R., et al.
Publicado: (2018)

Aging Kit Mutant Mice Develop Cardiomyopathy
por: Ye, Lei, et al.
Publicado: (2012)

The structural insights of stem cell factor receptor (c-Kit) interaction with tyrosine phosphatase-2 (Shp-2): An in silico analysis
por: Pati, Soumya, et al.
Publicado: (2010)

Allosteric Communication across the Native and Mutated KIT Receptor Tyrosine Kinase
por: Laine, Elodie, et al.
Publicado: (2012)

miR-631 Inhibits Intrahepatic Metastasis of Hepatocellular Carcinoma by Targeting PTPRE
por: Chen, Bingqing, et al.
Publicado: (2020)

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia
por: Murray, Heather C., et al.
Publicado: (2023)

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors
por: Puputti, Marjut, et al.
Publicado: (2009)

The Inherent Coupling of Intrinsically Disordered Regions in the Multidomain Receptor Tyrosine Kinase KIT
por: Ledoux, Julie, et al.
Publicado: (2022)

Role and significance of c-KIT receptor tyrosine kinase in cancer: A review
por: Sheikh, Emana, et al.
Publicado: (2022)

Mechanism of immune escape mediated by receptor tyrosine kinase KIT in thyroid cancer
por: Luo, Zhen, et al.
Publicado: (2023)

Receptor-type protein tyrosine phosphatases in cancer
por: Du, Yu, et al.
Publicado: (2015)

KIT and platelet-derived growth factor receptor α wild-type gastrointestinal stromal tumor associated with neurofibromatosis type 1: Two case reports
por: Kou, You-Wei, et al.
Publicado: (2019)

Erratum to: The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
por: Tóth, Béla, et al.
Publicado: (2020)

Role of intracellular tyrosines in activating KIT induced myeloproliferative disease
por: Ma, Peilin, et al.
Publicado: (2012)

Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants
por: Zhao, Jie, et al.
Publicado: (2014)

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo
por: Posch, Christian, et al.
Publicado: (2016)

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2017)

The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries
por: Pipek, Orsolya, et al.
Publicado: (2023)

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
por: Abbaspour Babaei, Maryam, et al.
Publicado: (2016)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations
por: Sandoval-Pérez, Angélica, et al.
Publicado: (2022)

Gastrointestinal Stromal Tumors with KIT Mutation Coexisting with Wild-type Gastrointestinal Stromal Tumors in a Patient with Neurofibromatosis Type 1
por: Li, Yang, et al.
Publicado: (2018)

Data on quantification of signaling pathways activated by KIT and PDGFRA mutants
por: Bahlawane, Christelle, et al.
Publicado: (2016)

Repurposing Ponatinib as a Potent Agent against KIT Mutant Melanomas
por: Han, Yong, et al.
Publicado: (2019)

Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA
por: Beadling, Carol, et al.
Publicado: (2013)

Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
por: Nannini, Margherita, et al.
Publicado: (2014)

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
por: Schroeder, Brett A., et al.
Publicado: (2020)

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022)

From KIT-mutated into wild-type: dedifferentiation of gastrointestinal stromal tumor in adolescent patient—a case report
por: Andrzejewska, Marta, et al.
Publicado: (2023)

C-kit receptor immunopositive interstitial cells (Cajal-type) in the porcine reproductive tract
por: Domino, Malgorzata, et al.
Publicado: (2017)

eBay auction templates starter kit
por: Miller, Michael
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_7crhb5afq7oji0ngto6ckg2k6v